Advanced Proteome Therapeutics Stock Probability of Future Pink Sheet Price Finishing Under 0.04

APTCF Stock  USD 0.0002  0.00  0.00%   
Advanced Proteome's future price is the expected price of Advanced Proteome instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Advanced Proteome Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Advanced Proteome Backtesting, Advanced Proteome Valuation, Advanced Proteome Correlation, Advanced Proteome Hype Analysis, Advanced Proteome Volatility, Advanced Proteome History as well as Advanced Proteome Performance.
  
Please specify Advanced Proteome's target price for which you would like Advanced Proteome odds to be computed.

Advanced Proteome Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Advanced Proteome for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Advanced Proteome can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Advanced Proteome generated a negative expected return over the last 90 days
Advanced Proteome has some characteristics of a very speculative penny stock
Advanced Proteome Therapeutics has accumulated 227.41 K in total debt with debt to equity ratio (D/E) of 4.65, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Advanced Proteome has a current ratio of 0.54, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Advanced Proteome until it has trouble settling it off, either with new capital or with free cash flow. So, Advanced Proteome's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Advanced Proteome sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Advanced to invest in growth at high rates of return. When we think about Advanced Proteome's use of debt, we should always consider it together with cash and equity.
Advanced Proteome Therapeutics has accumulated about 761.6 K in cash with (693.58 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow.

Advanced Proteome Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Advanced Pink Sheet often depends not only on the future outlook of the current and potential Advanced Proteome's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Advanced Proteome's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding39.7 M

Advanced Proteome Technical Analysis

Advanced Proteome's future price can be derived by breaking down and analyzing its technical indicators over time. Advanced Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Advanced Proteome Therapeutics. In general, you should focus on analyzing Advanced Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.

Advanced Proteome Predictive Forecast Models

Advanced Proteome's time-series forecasting models is one of many Advanced Proteome's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Advanced Proteome's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.

Things to note about Advanced Proteome

Checking the ongoing alerts about Advanced Proteome for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Advanced Proteome help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Advanced Proteome generated a negative expected return over the last 90 days
Advanced Proteome has some characteristics of a very speculative penny stock
Advanced Proteome Therapeutics has accumulated 227.41 K in total debt with debt to equity ratio (D/E) of 4.65, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Advanced Proteome has a current ratio of 0.54, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Advanced Proteome until it has trouble settling it off, either with new capital or with free cash flow. So, Advanced Proteome's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Advanced Proteome sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Advanced to invest in growth at high rates of return. When we think about Advanced Proteome's use of debt, we should always consider it together with cash and equity.
Advanced Proteome Therapeutics has accumulated about 761.6 K in cash with (693.58 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow.

Other Information on Investing in Advanced Pink Sheet

Advanced Proteome financial ratios help investors to determine whether Advanced Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Advanced with respect to the benefits of owning Advanced Proteome security.